Editas Medicine

EDIT

Valor de mercado US$ 361 mi

CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced two poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress, to be held October 27-30, 2026, in Hamburg, Germany.

Editas Medicine gains approval to launch the first-in-human phase I/II study of EDIT-401 in Australia, targeting LDL cholesterol through gene editing.

Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering  Company remains on track to begin patient dosing this year and report initial safety and tolerability data in the first quarter of 2027 New EDIT-401 preclinical data demonstrating durability of LDL-C reduction to be presented in oral presentation at AHA Scientific Sessions 2026 CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced it has received approval to initiate the Phase 1/2 Strive™ clinical trial of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia (HeFH) in Australia.

Editas Medicine NASDAQ: EDIT outlined its strategy as an in vivo gene-editing company and said it remains on track to dose patients this year in a clinical study of its lead program, EDIT-401, for lowering LDL cholesterol.

CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the grant of an inducement award to the Company's newly appointed Chief Medical Officer, Daniel Ory, M.D.

Editas Medicine NASDAQ: EDIT is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia, Chief Executive Officer Gilmore O'Neill said during a Wells Fargo discussion.

Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development

Editas (EDIT) reported earnings 30 days ago. What's next for the stock?

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September: Wells Fargo Healthcare Conference Format: Fireside ChatDate: Tuesday, September 8Time: 4:30 p.m.

Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.